Compare Cardinal Health Inc (CAH) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Roundhill Magnificent Seven ETF — how do they compare? Cardinal Health Inc trades at $228.8 (market cap $53.89B), while Roundhill Magnificent Seven ETF trades at $67.48. The key difference: Cardinal Health Inc pays a 0.89% dividend while Roundhill Magnificent Seven ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| CAH | MAGS | |
|---|---|---|
Market Cap | $53.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $239.71 | $70.94 |
52-Week Low | $146.04 | $55.39 |
Enterprise Value | $58.87B | — |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.99, down 1.02% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights the ETF's strong performance since launch but notes concentration risk and a recent pullback from 2026 highs. The fund provides equal-weight exposure to mega-cap tech stocks, with assets near $4.7 billion as of May 2026.
The outlook for MAGS hinges on the continued growth and AI monetization of its underlying holdings. Key opportunities include potential free cash flow expansion from hyperscalers, but risks involve high expectations, valuation compression, and the cyclical nature of tech leadership. Market sentiment is mixed, balancing long-term growth prospects against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
